Lates News

On June 4th, AstraZeneca announced that Imfinzi (generic name: durvalumab) has been approved by the National Medical Products Administration (NMPA) of China for use as a monotherapy in the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) who have not experienced disease progression after receiving platinum-based chemotherapy.